news
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
List view / Grid view
Research & Development (R&D)
article
The future of pharma R&D leadership
People, not platforms, will define the next era of innovation, explain Chiesi’s Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
news
Innovative nanoparticle research could restore antibiotic efficacy
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
news
UK ‘gaining pace’ with early-stage trials for advanced therapies
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
news
Hoth Therapeutics’ topical therapy shines in cancer toxicity trial
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
news
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
news
Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
news
Johnson & Johnson’s Caplyta demonstrates phase III promise for depression
Combination therapy comprising of an antidepressant and small molecule drug significantly boosted remission rates in adults with major depressive disorder.
article
ReiThera on vaccines and remaining nimble around emerging threats
As vaccines are buffeted by political pressures, the CDMO discussed its growth approach and some of its key collaborations.
news
Teva’s migraine biologic Ajovy marks phase III progress for paediatric patients
The monoclonal antibody could provide a new preventative treatment option for episodic migraines, new late-stage data suggests.
news
Polymer capsule drug delivery innovation demonstrates sustainability promise
Synthesis of the naturally-derived capsules provide a sustainable alternative to traditional, microplastic-contributing drug delivery options.
article
A software‑supported, AI‑assisted workflow for optimising LC gradient methods
Shimadzu introduces a novel automated artificial intelligence-driven HPLC method.
news
AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
news
Endotoxins research supports recombinant reagent use for pharma QC
Replacing LAL reagents with animal-free alternatives addresses industry commitments to improve QC practices’ ethics and sustainability.
webinar
Harnessing AI for more efficient clinical trials
5 January 2026 | By European Pharmaceutical Review
During this virtual panel, industry experts will discuss practical examples and considerations for applying AI in pharma’s clinical trials.
